|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/09/19 Biolase, Inc 10-Q 6/30/19 82:9.6M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 734K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 31K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 31K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 25K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 25K
12: R1 Document and Entity Information HTML 66K
13: R2 Consolidated Balance Sheets (Unaudited) HTML 109K
14: R3 Consolidated Balance Sheets (Unaudited) HTML 45K
(Parenthetical)
15: R4 Consolidated Statements Of Operations And HTML 99K
Comprehensive Loss (Unaudited)
16: R5 Consolidated Statements Of Shareholders' Equity HTML 57K
(Unaudited)
17: R6 Consolidated Statements Of Cash Flows (Unaudited) HTML 127K
18: R7 Description of Business and Basis of Presentation HTML 36K
19: R8 Summary of Significant Accounting Policies HTML 39K
20: R9 Revenue Recognition HTML 214K
21: R10 Stockholders' Equity HTML 296K
22: R11 Inventory HTML 45K
23: R12 Property, Plant, and Equipment HTML 66K
24: R13 Intangible Assets and Goodwill HTML 28K
25: R14 Accrued Liabilities HTML 115K
26: R15 Debt HTML 96K
27: R16 Leases HTML 72K
28: R17 Commitments and Contingencies HTML 32K
29: R18 Segment Information HTML 74K
30: R19 Concentrations HTML 113K
31: R20 Income Taxes HTML 30K
32: R21 Summary of Significant Accounting Policies HTML 72K
(Policies)
33: R22 Revenue Recognition (Tables) HTML 294K
34: R23 Stockholders' Equity (Tables) HTML 302K
35: R24 Inventory (Tables) HTML 46K
36: R25 Property, Plant, and Equipment (Tables) HTML 65K
37: R26 Accrued Liabilities (Tables) HTML 116K
38: R27 Debt (Tables) HTML 77K
39: R28 Leases (Tables) HTML 73K
40: R29 Segment Information (Tables) HTML 74K
41: R30 Concentrations (Tables) HTML 164K
42: R31 Description of Business and Basis of Presentation HTML 41K
- Additional Information (Detail)
43: R32 Summary of Significant Accounting Policies - HTML 34K
Additional Information (Detail)
44: R33 Revenue Recognition - Additional Information HTML 34K
(Detail)
45: R34 Summary of Opening and Closing Balances of HTML 35K
Contract Liabilities (Detail)
46: R35 Summary of Disaggregation of Revenues Related to HTML 32K
Geographic Areas (Detail)
47: R36 Summary of Revenues Disaggregated by Timing of HTML 32K
Goods and Services Transferred (Detail)
48: R37 Summary of Sales by End Market (Detail) HTML 32K
49: R38 Summary of Percentages of Sales by Product line HTML 39K
(Detail)
50: R39 Stockholders' Equity - Additional Information HTML 57K
(Detail)
51: R40 Classification of Compensation Expense Associated HTML 37K
with Share-Based Payments (Detail)
52: R41 Assumptions Used in Estimating Fair Value of Stock HTML 32K
Options Granted (Detail)
53: R42 Summary of Option Activity (Detail) HTML 69K
54: R43 Summary of Unvested Stock Option Activity (Detail) HTML 46K
55: R44 Cash Proceeds Along with Fair Value Disclosures HTML 32K
Related to Grants, Exercises and Vested Options
(Detail)
56: R45 Summary of Unvested Restricted Stock Units HTML 49K
(Detail)
57: R46 Summary of Warrant Activity (Detail) HTML 42K
58: R47 Components of Inventory (Detail) HTML 34K
59: R48 Inventory - Additional Information (Detail) HTML 27K
60: R49 Summary of Property, Plant, and Equipment (Detail) HTML 48K
61: R50 Property, Plant, and Equipment - Additional HTML 26K
Information (Detail)
62: R51 Intangible Assets and Goodwill - Additional HTML 32K
Information (Detail)
63: R52 Components of Accrued Liabilities (Detail) HTML 51K
64: R53 Changes in Initial Product Warranty Accrual and HTML 40K
Expenses Under Initial and Extended Warranties
(Detail)
65: R54 Accrued Liabilities - Additional Information HTML 32K
(Detail)
66: R55 Debt - Summary of Principal Outstanding and HTML 32K
Unamortized Discount (Detail)
67: R56 Debt - Additional Information (Detail) HTML 197K
68: R57 Debt - Summary of Future Minimum Principal and HTML 48K
Interest Payments (Detail)
69: R58 Leases - Additional Information (Detail) HTML 56K
70: R59 Leases - Information related to Right-of-use HTML 33K
Assets and Liabilities (Detail)
71: R60 Leases - Schedule of Maturities of Lease HTML 38K
Liabilities (Detail)
72: R61 Leases - Future Minimum Rental Commitments Under HTML 31K
Lease Agreements (Detail)
73: R62 Commitments and Contingencies - Additional HTML 55K
Information (Detail)
74: R63 Segment Information - Additional Information HTML 37K
(Detail)
75: R64 Summary of Net Revenue by Geographic Location HTML 32K
(Detail)
76: R65 Summary of Property, Plant and Equipment by HTML 31K
Geographic Location (Detail)
77: R66 Concentrations - Summary of Net Revenue from HTML 51K
Various Products (Detail)
78: R67 Concentrations - Additional Information (Detail) HTML 40K
79: R68 Income Taxes - Additional Information (Detail) HTML 35K
81: XML IDEA XML File -- Filing Summary XML 148K
80: EXCEL IDEA Workbook of Financial Reports XLSX 86K
6: EX-101.INS XBRL Instance -- biol-20190630 XML 2.70M
8: EX-101.CAL XBRL Calculations -- biol-20190630_cal XML 177K
9: EX-101.DEF XBRL Definitions -- biol-20190630_def XML 472K
10: EX-101.LAB XBRL Labels -- biol-20190630_lab XML 1.27M
11: EX-101.PRE XBRL Presentations -- biol-20190630_pre XML 943K
7: EX-101.SCH XBRL Schema -- biol-20190630 XSD 198K
82: ZIP XBRL Zipped Folder -- 0001564590-19-031164-xbrl Zip 163K
Exhibit 31.2
CERTIFICATION
I, John R. Beaver, certify that:
|
1. |
I have reviewed this quarterly report on Form 10-Q for the period ended June 30, 2019 of BIOLASE, Inc.; |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
|
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
c. |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
d. |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
5. |
I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
|
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
|
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
|
Date: August 9, 2019 |
By: |
/s/ JOHN R. BEAVER |
|
|
|
|
|
|
|
Executive Vice President and Chief Financial Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/9/19 | 4, S-3 | ||
| For Period end: | 6/30/19 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/29/22 Biolase, Inc. 424B5 1:399K Donnelley … Solutions/FA 2/09/21 Biolase, Inc. 424B5 1:495K Donnelley … Solutions/FA |